

Available online at www.sciencedirect.com
SciVerse ScienceDirect
journal homepage: www.elsevier.com/locate/poamed

Original Research Article

The sCD163/sTWEAK ratio in the peripheral blood mononuclear cells cultures correlates with disease severity in early systemic sclerosis


 Marek Bielecki^a, Krzysztof Kowal^b, Ewa Sacharzewska^c, Lech Chyczewski^d,
 Halina Car^e, Otylia Kowal-Bielecka^{f,*}
^aDepartment of Orthopedics and Traumatology, Medical University of Białystok, Poland^bDepartment of Allergology and Internal Medicine, Medical University of Białystok, Poland^cCenter of Experimental Medicine, Medical University of Białystok, Poland^dDepartment of Medical Pathomorphology, Medical University of Białystok, Poland^eDepartment of Experimental Pharmacology, Medical University of Białystok, Poland^fDepartment of Rheumatology and Internal Medicine, Medical University of Białystok, Poland

ARTICLE INFO

Article history:

Received 7 March 2013

Received in revised form

26 March 2013

Accepted 28 May 2013

Available online 31 May 2013

Keywords:

Systemic sclerosis

Scleroderma

CD163

TWEAK

Fibrosis

ABSTRACT

Introduction: CD163 is a scavenger receptor expressed exclusively on monocytes/macrophages and a decoy receptor for a TNF-related weak inducer of apoptosis (TWEAK), a multifunctional cytokine involved in the regulation of inflammatory response, angiogenesis and connective tissue remodeling. However, very little is known about the significance of CD163 and TWEAK interactions *in vivo*.

Aim: We hypothesized that CD163 and TWEAK interactions might play a role in the pathogenesis of systemic sclerosis (SSc).

Material and methods: The concentrations of soluble CD163 (sCD163) and soluble TWEAK (sTWEAK) were measured by the enzyme immunoassays in the supernatants of cultured peripheral blood mononuclear cells (PBMC) from 25 patients with early SSc and 16 healthy controls (HC). The sCD163/sTWEAK ratio was calculated and its association with disease parameters was assessed.

Results and discussion: The production of sTWEAK was comparable between SSc patients and HC ($p > .05$). The mean concentration of sCD163 and the mean sCD163/sTWEAK ratio were significantly greater in SSc patients as compared with HC ($p < .05$ for both). However, only sCD163/sTWEAK ratio, but not sCD163 or sTWEAK alone, correlated with the modified Rodnan skin score (Spearman $R=0.46$) and, inversely, with forced vital capacity ($R=-0.49$) and diffusing capacity of the lungs for carbon monoxide ($R=-0.50$) in SSc patients.

Conclusions: We showed that there is an imbalance in the production of sCD163 and sTWEAK by the PBMC from SSc patients resulting in increased sCD163/sTWEAK ratio. Correlation of sCD163/sTWEAK ratio in PBMC supernatants with the severity of skin and

*Correspondence to: Department of Rheumatology and Internal Medicine, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland. Tel.: +48 857 468 482; fax: +48 857 468 606.

E-mail addresses: otyliab@tlen.pl, otylia@umb.edu.pl (O. Kowal-Bielecka).

lung involvement indicates that interaction of these two molecules might affect the development of SSc.

© 2013 Warmińsko-Mazurska Izba Lekarska w Olsztynie. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

1. Introduction

Systemic sclerosis (SSc) is a chronic autoimmune disease affecting skin and internal organs. Pathogenesis of SSc is not fully understood. However, activation of inflammatory cells, vascular injury and increased production of connective tissue by activated fibroblast are considered key events in the development of SSc.¹

CD163 is a scavenger receptor for haptoglobin–hemoglobin complexes and is expressed solely on macrophages and monocytes.¹³ Proteolytic shedding of the membrane-bound CD163 produces soluble CD163 (sCD163) which can be detected in body fluids.²¹ A role of sCD163 molecule is not well understood; however available data indicate that it may play a role in the regulation of inflammatory and immune reactions.^{8,13,21} It has been shown that concentration of sCD163 increases in the peripheral blood of patients with inflammatory conditions such as sepsis, asthma or autoimmune diseases including rheumatoid arthritis and SSc.^{12,13,17,21,24,25} Recently, it has been shown that CD163 can bind and neutralize a tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK).⁵ TWEAK is a member of the TNFalpha superfamily of cytokines and has been shown to exert a broad range of biological activities generally of proinflammatory nature.^{7,11,28} TWEAK has also been shown to regulate angiogenesis and to affect connective tissue remodeling.^{6,7,28} Binding of TWEAK by CD163 may modulate its biological functions. Indeed, it has recently been shown that sCD163/sTWEAK ratio is a better predictor of subclinical arteriosclerosis as compared with sCD163 or sTWEAK alone, indicating that CD163/TWEAK interactions may play an important role *in vivo*.²⁰

It has recently been shown that the peripheral blood mononuclear cells (PBMC) isolated from patients with SSc *in vitro* spontaneously release significantly greater amounts of sCD163 as compared with healthy controls (HC) but the release of sTWEAK by PBMC was not different between SSc patients and HC.^{3,4}

2. Aim

The aim of this study was to investigate the mutual relations of *in vitro* sCD163 and sTWEAK production by PBMC of patients with early SSc in relation to its clinical features.

3. Material and methods

3.1. Patients

In this study 25 patients with SSc (19 women and 6 men) were investigated. Since pathogenic events, which could also represent potential therapeutic targets, are believed to take

place early in the evolution of the disease, only patients with early SSc were selected for this study.^{2,18} In agreement with generally accepted criteria, early SSc was defined as shorter than 3 years in diffuse SSc (dSSc) patients or shorter than 5 years duration in patients with limited SSc (lSSc) measured from the first non-Raynaud's phenomenon clinical symptom attributable to SSc, which corresponds to the early phase of overt disease.¹⁹ All patients selected for the study fulfilled the ACR classification criteria for SSc and/or the criteria of early SSc as proposed by LeRoy et al.^{15,26} Only patients who had not taken any immunosuppressive therapies or in whom immunosuppressive therapies had been stopped at least 6 months before blood collection were considered eligible.

SSc patients were evaluated as described in previous studies.^{3,4} Shortly, clinical assessment included evaluation of the subtype of the disease, dSSc or lSSc, as defined by LeRoy et al.¹⁴; duration of Raynaud's phenomenon and duration of the disease (calculated from the time of the first non-Raynaud's symptom attributable to SSc), extent of skin involvement (using the modified Rodnan skin score, mRSS), the presence of scleroderma interstitial lung disease (ILD), pulmonary hypertension, digital ulcers and scleroderma renal crisis. The severity of lung involvement was assessed by measurement of forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO). Laboratory assessment consisted of evaluation of the presence of anti-nuclear antibodies (ANA), anticentromere antibodies (ACA) and anti-topoisomerase I antibodies (anti-topo I) as well as measurement of erythrocyte sedimentation rate (ESR) and serum concentration of C-reactive protein (CRP). Clinical characteristics of the patients are shown in Table 1.

Control group consisted of 16 age- and sex-matched healthy controls (HC): 12 women and 4 men. The mean (\pm SD, range) age of the HC was 41 (\pm 14, 20–70) years. There were no significant differences in the sex or age between SSc patients and the HC.

Study protocol was approved by the local ethics committee and all patients gave appropriate informed consent.

3.2. PBMC cultures and measurements of sCD163 and sTWEAK in supernatants

Peripheral blood mononuclear cells (PBMC) were isolated from the whole blood using density gradient centrifugation on Histopaque and incubated in RPMI medium supplemented with 5% fetal calf serum at a density of 10^5 cells/mL and cultured at 37°C under 5% CO₂ for 24 h as described elsewhere.^{3,4} Subsequently the cells were centrifuged and supernatants were collected and frozen at –80°C until measurements were performed. The concentrations of sCD163 and sTWEAK in the PBMC supernatants were measured using commercially available enzyme immunoassay (ELSA) kits

Download English Version:

<https://daneshyari.com/en/article/2678675>

Download Persian Version:

<https://daneshyari.com/article/2678675>

[Daneshyari.com](https://daneshyari.com)